Valcrest Pharmaceuticals specializes in the development and commercialization of novel pharmaceutical products to address the special needs of patients with ultra-rare orphan diseases. The founding members of Valcrest have deep experience in the rare disease market and specific competencies in dealing with FDA regulatory requirements, clinical development, manufacturing, API sourcing, formulation development and product commercialization.
Valcrest, in collaboration with a partner company, is currently advancing an innovative therapy for the treatment of Mastocytosis, a rare disorder of both children and adults caused by the presence of an excess of mast cells (mastocytes) and CD34+ mast cell precursors. People affected by Mastocytosis are susceptible to itching, hives, and anaphylactic shock, caused by the release of histamine from mast cells. Val-220, a novel oral therapy for the systemic treatment of Mastocytosis, has demonstrated an ability to stabilize mast cells and therefore control the inappropriate release of histamine.
Valcrest is actively looking to add to its portfolio of new rare disease products and expects to add several additional products into development shortly.
Contact Valcrest at firstname.lastname@example.org.